Episode 80 with Dr. Kaarina Kowalec on adverse MS drug reactions
Approximately 1 in 50 people with MS in British Columbia, Canada, developed drug-induced liver injury with about three months of exposure to interferon-beta IFN-β. The study of adverse drug reactions will help minimize or prevent the toxicity of MS drugs, a major clinical objective.
Approximately 1 in 50 people with MS in British Columbia, Canada, developed drug-induced liver injury with about three months of exposure to interferon-beta IFN-β. The study of adverse drug reactions will help minimize or prevent the toxicity of MS drugs, a major clinical objective.
Clinical Research, Drug Development